Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 14 | 2022 | 353 | 4.400 |
Why?
|
| Ovarian Neoplasms | 8 | 2021 | 66 | 3.190 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 3 | 2021 | 8 | 1.870 |
Why?
|
| Germ-Line Mutation | 4 | 2021 | 11 | 1.640 |
Why?
|
| Genes, BRCA1 | 3 | 2020 | 9 | 1.450 |
Why?
|
| DNA-Binding Proteins | 4 | 2021 | 254 | 1.210 |
Why?
|
| Genes, BRCA2 | 3 | 2020 | 9 | 1.160 |
Why?
|
| Endometrial Neoplasms | 2 | 2021 | 10 | 0.890 |
Why?
|
| Genes, p53 | 3 | 2020 | 15 | 0.880 |
Why?
|
| Female | 24 | 2022 | 14388 | 0.870 |
Why?
|
| Genetic Testing | 2 | 2021 | 52 | 0.870 |
Why?
|
| Phthalazines | 2 | 2020 | 5 | 0.860 |
Why?
|
| Piperazines | 2 | 2020 | 76 | 0.810 |
Why?
|
| Mutation | 4 | 2021 | 311 | 0.790 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2021 | 3 | 0.760 |
Why?
|
| RNA Helicases | 1 | 2021 | 1 | 0.760 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2021 | 1 | 0.760 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 3 | 0.690 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 185 | 0.690 |
Why?
|
| Hematopoiesis | 1 | 2018 | 11 | 0.610 |
Why?
|
| Chimerism | 1 | 2018 | 3 | 0.610 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 3 | 0.610 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2018 | 2 | 0.610 |
Why?
|
| Humans | 24 | 2022 | 26010 | 0.610 |
Why?
|
| Nitriles | 2 | 2017 | 12 | 0.610 |
Why?
|
| BRCA2 Protein | 1 | 2018 | 3 | 0.610 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 7 | 0.580 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 4 | 0.580 |
Why?
|
| Triazoles | 1 | 2017 | 27 | 0.570 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 24 | 0.570 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 35 | 0.570 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 85 | 0.550 |
Why?
|
| Receptor, ErbB-2 | 3 | 2014 | 47 | 0.540 |
Why?
|
| Adult | 10 | 2020 | 7358 | 0.520 |
Why?
|
| Estrogens | 1 | 2015 | 25 | 0.500 |
Why?
|
| False Positive Reactions | 1 | 2015 | 32 | 0.500 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 14 | 0.500 |
Why?
|
| Estradiol | 1 | 2015 | 37 | 0.500 |
Why?
|
| Immunoassay | 1 | 2015 | 37 | 0.500 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2014 | 45 | 0.480 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2014 | 5 | 0.470 |
Why?
|
| Middle Aged | 11 | 2021 | 8503 | 0.440 |
Why?
|
| Aged | 8 | 2021 | 8702 | 0.410 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 230 | 0.410 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2012 | 4 | 0.410 |
Why?
|
| Ribonucleotide Reductases | 1 | 2012 | 1 | 0.410 |
Why?
|
| Platinum | 1 | 2012 | 3 | 0.410 |
Why?
|
| Biopsy | 4 | 2017 | 199 | 0.400 |
Why?
|
| Cell Proliferation | 4 | 2021 | 161 | 0.390 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 114 | 0.390 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2012 | 61 | 0.380 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2022 | 373 | 0.370 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 7 | 0.370 |
Why?
|
| Indoles | 1 | 2011 | 34 | 0.370 |
Why?
|
| Protein Kinase C | 1 | 2011 | 47 | 0.370 |
Why?
|
| DNA Mismatch Repair | 2 | 2021 | 5 | 0.330 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2008 | 2 | 0.310 |
Why?
|
| Genes, erbB-2 | 1 | 2008 | 6 | 0.310 |
Why?
|
| Antigens, Neoplasm | 1 | 2008 | 38 | 0.310 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 87 | 0.310 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2015 | 28 | 0.300 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 2 | 2017 | 4 | 0.280 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 313 | 0.270 |
Why?
|
| Retrospective Studies | 4 | 2022 | 3294 | 0.260 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 179 | 0.210 |
Why?
|
| Cancer Survivors | 1 | 2022 | 12 | 0.210 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 176 | 0.210 |
Why?
|
| Coculture Techniques | 1 | 2021 | 27 | 0.200 |
Why?
|
| Fibroblasts | 1 | 2021 | 56 | 0.190 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 50 | 0.190 |
Why?
|
| Precision Medicine | 1 | 2021 | 25 | 0.190 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 43 | 0.190 |
Why?
|
| Genomics | 1 | 2021 | 53 | 0.190 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2020 | 5 | 0.180 |
Why?
|
| Apoptosis | 1 | 2021 | 193 | 0.180 |
Why?
|
| Animals | 2 | 2021 | 3389 | 0.180 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2019 | 1 | 0.170 |
Why?
|
| Folic Acid Deficiency | 1 | 2019 | 5 | 0.170 |
Why?
|
| Pilot Projects | 1 | 2020 | 377 | 0.160 |
Why?
|
| Neoplasm Metastasis | 3 | 2014 | 93 | 0.160 |
Why?
|
| Lymphatic Metastasis | 2 | 2012 | 80 | 0.160 |
Why?
|
| Cadherins | 2 | 2017 | 34 | 0.160 |
Why?
|
| Pedigree | 1 | 2017 | 55 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2017 | 51 | 0.140 |
Why?
|
| Neoplasms | 1 | 2019 | 219 | 0.140 |
Why?
|
| Receptors, Estrogen | 2 | 2015 | 57 | 0.140 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2016 | 1 | 0.140 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2016 | 1 | 0.140 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 4 | 0.140 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 5 | 0.140 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 7 | 0.140 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 335 | 0.130 |
Why?
|
| Liver | 1 | 2017 | 123 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 61 | 0.130 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 80 | 0.130 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 22 | 0.130 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 21 | 0.130 |
Why?
|
| Postmenopause | 1 | 2015 | 49 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2014 | 40 | 0.120 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 2 | 0.120 |
Why?
|
| Hydroxybutyrates | 1 | 2014 | 6 | 0.120 |
Why?
|
| Aniline Compounds | 1 | 2014 | 35 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2014 | 33 | 0.120 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 4658 | 0.110 |
Why?
|
| Colitis, Ulcerative | 1 | 2014 | 62 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 55 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 75 | 0.110 |
Why?
|
| Blotting, Western | 1 | 2013 | 133 | 0.110 |
Why?
|
| Cell Movement | 1 | 2013 | 77 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 185 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2013 | 124 | 0.110 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 200 | 0.110 |
Why?
|
| Axilla | 1 | 2012 | 11 | 0.100 |
Why?
|
| Deoxycytosine Nucleotides | 1 | 2012 | 1 | 0.100 |
Why?
|
| Thiosemicarbazones | 1 | 2012 | 1 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2013 | 475 | 0.100 |
Why?
|
| DNA Damage | 1 | 2012 | 24 | 0.100 |
Why?
|
| Immunoblotting | 1 | 2012 | 55 | 0.100 |
Why?
|
| Gynecology | 1 | 2012 | 8 | 0.100 |
Why?
|
| Histones | 1 | 2012 | 24 | 0.100 |
Why?
|
| Pyridines | 1 | 2012 | 36 | 0.100 |
Why?
|
| Cell Survival | 1 | 2012 | 111 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2012 | 62 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2012 | 40 | 0.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2011 | 2 | 0.090 |
Why?
|
| Protein Kinase C beta | 1 | 2011 | 7 | 0.090 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 10 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 6 | 0.090 |
Why?
|
| Family | 1 | 2012 | 93 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 66 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 44 | 0.090 |
Why?
|
| Mice | 1 | 2013 | 1280 | 0.080 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2008 | 2 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2008 | 6 | 0.080 |
Why?
|
| Gene Dosage | 1 | 2008 | 16 | 0.080 |
Why?
|
| Gene Amplification | 1 | 2008 | 18 | 0.080 |
Why?
|
| Gene Deletion | 1 | 2008 | 31 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2007 | 4 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2007 | 5 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 7 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 192 | 0.070 |
Why?
|
| Prognosis | 1 | 2008 | 750 | 0.060 |
Why?
|
| Carcinoma, Lobular | 1 | 2005 | 18 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2012 | 3292 | 0.050 |
Why?
|
| Breast Density | 1 | 2022 | 4 | 0.050 |
Why?
|
| Mammography | 1 | 2022 | 47 | 0.050 |
Why?
|
| Mass Screening | 1 | 2022 | 166 | 0.050 |
Why?
|
| Breast Neoplasms, Male | 1 | 2019 | 9 | 0.040 |
Why?
|
| Internationality | 1 | 2019 | 24 | 0.040 |
Why?
|
| Folic Acid | 1 | 2019 | 13 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 64 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 199 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2022 | 1140 | 0.040 |
Why?
|
| Age Factors | 1 | 2019 | 744 | 0.040 |
Why?
|
| Butadienes | 1 | 2014 | 1 | 0.030 |
Why?
|
| Crotonates | 1 | 2014 | 3 | 0.030 |
Why?
|
| Toluidines | 1 | 2014 | 3 | 0.030 |
Why?
|
| Chromones | 1 | 2014 | 6 | 0.030 |
Why?
|
| Isoxazoles | 1 | 2014 | 5 | 0.030 |
Why?
|
| Morpholines | 1 | 2014 | 11 | 0.030 |
Why?
|
| Pyrazines | 1 | 2014 | 10 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 10 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2014 | 17 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 42 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 35 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2014 | 5 | 0.030 |
Why?
|
| Adalimumab | 1 | 2014 | 16 | 0.030 |
Why?
|
| Mastectomy | 1 | 2014 | 21 | 0.030 |
Why?
|
| Diarrhea | 1 | 2014 | 31 | 0.030 |
Why?
|
| Imidazoles | 1 | 2014 | 55 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 713 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2007 | 25 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2005 | 23 | 0.020 |
Why?
|
| Male | 1 | 2019 | 14000 | 0.010 |
Why?
|